The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FDA OKs injectable antibiotic for MRSA, other infections

Article-FDA OKs injectable antibiotic for MRSA, other infections

Rockville, Md. — The Food and Drug Administration (FDA) has approved the injectable antibiotic ceftaroline fosamil (Teflaro, Forest Laboratories) for treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin-structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA), reports.

The drug’s safety and effectiveness were evaluated in four phase 3 clinical trials in patients age 18 and older (two phases each for CABP and ABSSSI). In the CABP trials, the comparator antibacterial treatment was ceftriaxone (Rocephin, Roche) and in the ABSSSI trials, vancomycin (Vancocin, ViroPharma) plus aztreonam (Azactam, Bristol-Myers Squibb).

In the CABP trials, 1,231 adult patients received ceftaroline fosamil or ceftriaxone. In both trials, ceftaroline fosamil’s effectiveness was comparable to ceftriaxone’s. In the ABSSSI trials, 1,396 adult patients received ceftaroline fosamil or vancomycin plus aztreonam. In these trials, ceftaroline fosamil was comparable to vancomycin plus aztreonam.

The most commonly reported side effects in patients treated with ceftaroline fosamil were diarrhea, nausea and rash.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.